From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
October 1, 2018
Philadelphia, PA, October 1, 2018 – IntegriChain, a leading life sciences commercial analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation, adherence, and persistence, today announced that Dave Weiss, Executive Director of Industry Solutions and industry expert on 340B analytics, will chair the 340B Track at the Medicaid Drug Rebate Program Summit (MDRP). The MDRP 340B track is slated for October 2 from 1:45 pm to 5:20 pm, and 340B sessions dominate this year’s MDRP agenda overall.
“The 340B program has experienced explosive growth in the past several years, and the number of covered entities, contract pharmacies, and participating hospitals is higher than ever,” said Weiss. “Recent research shows that the original intent of the program, subsidizing care for underserved patient populations, is not being fulfilled and program non-compliance is increasing overall healthcare costs. The pharma industry is clearly searching for a solution until new regulations address these issues. A number of leading brands have recently initiated projects with us to identify and monitor 340B duplicate discounts and diversions tied to Medicaid and suspicious purchase volumes so that can have better, more productive reviews with their 340B customers.”
About IntegriChain IntegriChain is a life sciences commercial analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation, adherence, and persistence. Our ICyte Platform and solutions uniquely focus on what happens after the patient and provider commit to therapy. More than 140 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA; the Access Management Operations center is in Ambler, PA; and the Patient Services Center is in Atlanta, GA. For more information, visit www.integrichain.com or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com
Tags: 340B, MDRP, speaker
Save the date!
Webinars & Resources
See List
